journal article·2023-12-31Open access

Identification of stemness subtypes and features to improve endometrial cancer treatment using machine learning

Xiaoqin Lu, Yanqi Ying, Wenyi Zhang, Rui Li, Wuliang Wang

Abstract

Endometrial cancer is one of the most common malignant tumours in women, and cancer stem cells are known to play an important role in its growth, invasion, metastasis, and drug resistance. Immunotherapy for endometrial cancer is still under research. In this study, a total of 547 endometrial cancer cases were randomly divided into training set (351 cases) set and test set (196 cases). The stemness index of patients was calculated using the One-Class Logistic Regression (OCLR) machine learning algorithm to explore the clinicopathological differences between index levels. Stemness subtypes were determined according to the characteristics of cancer stemness and their clinicopathological characteristics, immune features, and therapeutic effects were described. Our study suggests that endometrial cancer is classified into two stemness subtypes. Stemness subtypes, which are associated with its clinical features, may be independent prognostic factors for endometrial cancer. The stemness subtypes differed significantly in immune activity, immune cell infiltration, and the immune microenvironment, including sensitivity to chemotherapeutic drugs and potential therapeutic compounds. Algorithms were utilised to construct a stemness subtype prediction model and predictor. These findings will provide guidance for the clinical diagnosis, treatment, and prognosis of endometrial cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Cells and Metastasis · Endometrial and Cervical Cancer Treatments · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Funding

Department of Science and Technology · Department of Education · Henan Provincial Health Commission · Clinical Medical Research Center of Gynecology and Obstetrical Diseases

References (52)

Show source-provided references
1. 10.1146/annurev-pathol-020117-04360910.1146/annurev-pathol-020117-043609 ↗
2. 10.3322/caac.2149210.3322/caac.21492 ↗
3. 10.3322/caac.2159010.3322/caac.21590 ↗
4. 10.1136/ijgc-2020-00182210.1136/ijgc-2020-001822 ↗
5. 10.1016/j.cell.2018.03.03410.1016/j.cell.2018.03.034 ↗
6. 10.1038/nrc174010.1038/nrc1740 ↗
7. 10.1038/3510216710.1038/35102167 ↗
8. 10.1016/j.semcancer.2006.05.00110.1016/j.semcancer.2006.05.001 ↗
9. 10.1038/nrc326110.1038/nrc3261 ↗
10. 10.1016/j.stem.2014.02.00610.1016/j.stem.2014.02.006 ↗
11. 10.1093/glycob/cwy00110.1093/glycob/cwy001 ↗
12. 10.1038/nrclinonc.2017.4410.1038/nrclinonc.2017.44 ↗
13. 10.1016/j.cell.2017.03.04210.1016/j.cell.2017.03.042 ↗
14. Esparza R · J Neurooncol · 2015 · 123 · 44910.1007/s11060-015-1729-x ↗
15. 10.1007/s12253-018-0535-010.1007/s12253-018-0535-0 ↗
16. 10.3390/cancers1111182010.3390/cancers11111820 ↗
17. Dawood S · Oncology (Williston Park) · 2014 · 28 · 1101
18. Vander Linden C · Front Oncol · 2019 · 9 · 15910.3389/fonc.2019.00159 ↗
19. 10.1530/REP-09-041110.1530/REP-09-0411 ↗
20. 10.1016/j.ebiom.2018.12.04410.1016/j.ebiom.2018.12.044 ↗
21. 10.1016/j.biopha.2018.09.04110.1016/j.biopha.2018.09.041 ↗
22. 10.1002/ijc.3296510.1002/ijc.32965 ↗
23. 10.3389/fimmu.2020.0162410.3389/fimmu.2020.01624 ↗
24. 10.1038/ni.270310.1038/ni.2703 ↗
25. 10.1016/B978-0-12-800267-4.00003-110.1016/B978-0-12-800267-4.00003-1 ↗
26. 10.1146/annurev-immunol-031210-10132410.1146/annurev-immunol-031210-101324 ↗
27. Marinelli O · Front Oncol · 2019 · 9 · 107310.3389/fonc.2019.01073 ↗
28. Brooks RA · CA Cancer J Clin · 2019 · 69 · 25810.3322/caac.21561 ↗
29. 10.3389/fimmu.2020.0036910.3389/fimmu.2020.00369 ↗
30. 10.18632/aging.10281710.18632/aging.102817 ↗
31. 10.1111/jcmm.1540810.1111/jcmm.15408 ↗
32. 10.1158/0008-5472.CAN-18-068910.1158/0008-5472.CAN-18-0689 ↗
33. 10.1177/1758835922109621910.1177/17588359221096219 ↗
34. 10.1016/j.intimp.2020.10670010.1016/j.intimp.2020.106700 ↗
35. Cancer stat facts: Uterine cancer. National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/corp.html. (Accessed on September 28, 2019).
36. 10.1245/s10434-009-0736-610.1245/s10434-009-0736-6 ↗
37. 10.1016/S0140-6736(09)62163-210.1016/S0140-6736(09)62163-2 ↗
38. 10.1016/S1470-2045(18)30079-210.1016/S1470-2045(18)30079-2 ↗
39. National Comperhensive Cancer Network. Available online: https://www.nccn.org/professionals/physician_gls/pdf/uterine_blocks.pdf. (Accessed on September 28, 2019).
40. 10.1016/j.ygyno.2006.02.01110.1016/j.ygyno.2006.02.011 ↗
41. Lajer H · Int J Gynecol Cancer · 2010 · 20 · 1307
42. 10.3390/ijms2306341210.3390/ijms23063412 ↗
43. 10.4161/cc.7.2.520710.4161/cc.7.2.5207 ↗
44. 10.3390/cancers1305113610.3390/cancers13051136 ↗
45. 10.1016/j.ygyno.2013.03.00510.1016/j.ygyno.2013.03.005 ↗
46. Dong P · J Transl Med · 2014 · 12 · 23110.1186/s12967-014-0231-0 ↗
47. 10.1016/j.febslet.2014.12.00210.1016/j.febslet.2014.12.002 ↗
48. 10.1001/jamaoncol.2015.215110.1001/jamaoncol.2015.2151 ↗
49. 10.1126/science.aan673310.1126/science.aan6733 ↗
50. 10.1200/JCO.2017.72.595210.1200/JCO.2017.72.5952 ↗
51. Fleming GF · J Clin Oncol · 2017 · 35 · 558510.1200/JCO.2017.35.15_suppl.5585 ↗
52. 10.1056/NEJMoa150059610.1056/NEJMoa1500596 ↗